Sort
82,697 grants matching “vaccine development”
Molecular approaches to understand vector-host and vector-pathogen interactions
$943,034Jesus Valenzuela · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
NLM R&D Tools for Standardization of Electronic Medical Record and Personal Health Record
$943,018Clement McDonald · National Library Of Medicine · ZIA · FY2015 · LM
Preclinical Development of Ad26/Env Vaccines for HIV
$942,991Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2022 · AI
TASK X26: Immunogenicity and Efficacy Testing of Zika Vaccine Candidates in Animal Models
$942,954Randi Hornback · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2018 · AI
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
$942,943Stephen Lev Hoffman · Sanaria, Inc. · U01 · FY2023 · AI
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
$942,943Stephen Lev Hoffman · Sanaria, Inc. · U01 · FY2021 · AI
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
$942,943Stephen Lev Hoffman · Sanaria, Inc. · U01 · FY2022 · AI
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
$942,943Stephen Lev Hoffman · Sanaria, Inc. · U01 · FY2024 · AI
Bytes to Bedside: Collaborative Development for Translational Clinical Decision Support
$942,867Eric Steven Kirkendall · Wake Forest University Health Sciences · UG3 · FY2025 · TR
High accuracy automated tick classification using computer vision
$942,842Autumn Goodwin · Vectech, Llc · R44 · FY2024 · AI
Strategies for targeting T follicular helper cells to improve HIV Env vaccine immunogenicity and efficacy
$942,815Ellen Elizabeth Sparger · University Of California At Davis · P01 · FY2025 · AI
HIV-Receptor Interactions and Related Anti-HIV Strategies
$942,587Edward Berger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Broad spectrum therapeutics targeting resolvase enzymes
$942,460Frederic D Bushman · University Of Pennsylvania · U01 · FY2010 · AI
Optimizing the graft versus leukemia effect for pediatric ALL
$942,362Terry Fry · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
DISSEMINATED TUBERCULOSIS IN HIV INFECTION
$942,272Dartmouth College · R01 · FY2003 · AI
Project 1 - Development of mRNA Immunogens for Protective Antibody Induction
$942,168Barton F Haynes · Duke University · U19 · FY2020 · AI
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
$942,132Pablo Tamayo · University Of California, San Diego · U01 · FY2021 · CA
Immunosuppression-free transplantation through placental mimicry
$942,000Jessica Diane Weaver · Arizona State University-Tempe Campus · DP2 · FY2024 · AI
Novel vaccine against Norovirus
$941,991Xi Jiang · Cincinnati Childrens Hosp Med Ctr · R01 · FY2010 · AI
Pathogenic determinants of the SIV envelope transmembrane cytoplasmic domain
$941,644James A Hoxie · University Of Pennsylvania · R01 · FY2009 · AI
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE AND PANAMA
$941,456Gregory James Mertz · University Of New Mexico · U19 · FY2008 · AI
Immunoprevention and immunosurveillance of human non-viral cancers
$941,449Olivera J Finn · University Of Pittsburgh At Pittsburgh · R35 · FY2016 · CA
Core B - Genomics Core
$941,278Steven M Wolinsky · Icahn School Of Medicine At Mount Sinai · U19 · FY2016 · AI
Naturally-Acquired and Vaccine-Mediated Immunity to Leptospirosis
$941,162Albert Icksang Ko · Yale University · R01 · FY2018 · AI
Evaluation of the Immunogenicity and Efficacy of a MVA-HIV Prime, gp145 HIV protein/ALFA-adjuvanted Boost Vaccine Regimen with SHIV-CH505 Challenge in Male Rhesus Macaques
$941,082Ranajit Pal · Advanced Bioscience Laboratories, Inc. · N01 · FY2018 · AI